Welcome back to the Insider Trades Series – A weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The trades have all taken place between 23 December 2024 and 2 January 2025. Directors have up to 5 business days to notify the ASX of their trades.
Ticker | Company | Date | Director | Price | Value |
---|---|---|---|---|---|
Westpac | 31/12/24 | $32.40 | $214,311 | ||
Arena REIT | 24/12/24 | $3.92 | $35,161 | ||
Iluka Resources | 27/12/24 | $4.89 | $34,197 |
Not a whole lot. Westpac's Andy Maguire and Iluka's Peter Smith made their initial share purchases in December after joining the company's board in recent months.
Ticker | Company | Date | Director | Price | Value |
---|---|---|---|---|---|
Harvey Norman | 23/12/24 | $4.73 | $1,408,923 | ||
Harvey Norman | 27/12/24 | $4.73 | $1,392,630 | ||
Harvey Norman | 24/12/24 | $4.76 | $445,659 | ||
Scentre Group | 23/12/24 | $1.735 | $173,500 | ||
Scentre Group | 24/12/24 | $3.50 | $101,500 |
Harvey Norman CEO Kay Page has sold shares worth approximately $3.24 million since December 20, 2024, significantly exceeding the 250,908 shares she received through exercised options on January 2. The company's most recent update came at its November 27 AGM, which reported year-to-date sales revenue growth of 1.7% from July to October. In response, UBS analysts downgraded the stock to Neutral from Buy while maintaining a $5.00 target price, citing caution due to the company's product mix being weighted toward late-cycle consumer upturn categories. The analysts view the company's property portfolio as a key valuation support, with a gross asset value of $3.39 per share.
Scentre Group CEO Elliott Rusanow has sold $275,000 worth of shares across two transactions since December 23, following earlier sales totaling $692,000 on December 18 and 20, 2024. This marks his first share sale since becoming CEO in October 2022. The retail REIT enjoyed strong performance in 2024 with a 20.9% gain, driven largely by falling bond yields and increasing expectations of rate cuts. Morgan Stanley maintains an Overweight rating on the stock with a $4.35 target price as of November 26, 2024.
Get the latest news and insights direct to your inbox